Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rebamipide - Otsuka Pharmaceutical

Drug Profile

Rebamipide - Otsuka Pharmaceutical

Alternative Names: MCT-SR; Mucosta; OPC-12759; OPC-12759E; OPC759; Pramipide; Proamipide

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Acucela; Otsuka Pharmaceutical
  • Class Amino acids; Antiulcers; Cytoprotectives; Eye disorder therapies; Quinolones; Small molecules
  • Mechanism of Action Oxygen radical formation antagonists; Oxygen radical scavengers; Prostaglandin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes; Gastric ulcer; Gastritis
  • Phase II Stomatitis
  • Discontinued Cancer; Diabetes mellitus; Keratoconjunctivitis; NSAID-induced ulcer; Ulcerative colitis; Xerostomia

Most Recent Events

  • 06 Dec 2019 Korea Otsuka Pharmaceutical plans a phase III trial in Gastritis (for a sustained release formulation) (037-402-00039; NCT04189705)
  • 24 Jul 2019 Otsuka Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (PO, Controlled release) (NCT04150146)
  • 05 Jul 2019 Phase-I clinical trials in Gastric ulcer (In volunteers) in South Korea (PO, Controlled release) (NCT04150146)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top